


OMTM, Volume 26










Supplemental information










**Pre-existing anti-drug antibodies
in Fabry disease show less affinity
for pegunigalsidase alfa**










Malte Lenders, Solvey Pollmann, Melina Terlinden, and Eva Brand





















Supplemental Figure 1: Correlation of individual total inhibitory capacities [mg] of agalsidase-alfa versus agalsidase-beta. N=10.










































Supplemental Figure 2: Individual ELISA-based affinity measures of pre-existing anti- α -galactosidase A antibodies against agalsidase-alfa, agalsidase-beta and pegunigalsidase-alfa. The horizontal lines mark respective B_{max} values. PRX102: pegunigalsidase-alfa.










Supplemental Figure 3: Individual cross-ELISAs versus agalsidase-beta and pegunigalsidase-alfa. Beta: agalsidase-beta, PRX: pegunigalsidase-alfa.



Supplemental Figure 4: Individual titration curves to determine inhibitory capacities against AGALs. The dotted line at 10% inhibition highlights the saturation cut off. AGAL: α -galactosidase A, PRX-102: pegunigalsidase-alfa.